2nd Quarter - Report

INNOVATIVE FEDERAL STRATEGIES, LLC for ACURX PHARMACEUTICALS, INC.

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

H.R.9260/S.____, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, 2027, Title II, all provisions related research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.

LobbyistCovered position, as disclosed
ERYNN D HOOK —
CARL KIME —
LETITIA WHITE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 9260 (119th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.